Versiti - VBRI President and CEO Chris Miskel Named One of Wisconsin’s Most Influential Business Leaders

News

VBRI President and CEO Chris Miskel Named One of Wisconsin’s Most Influential Business Leaders

Milwaukee — January 02, 2026

Versiti Blood Research Institute is proud to announce that Chris Miskel, president and CEO of Versiti, has been named to BizTimes Media’s Wisconsin 275, an annual publication and list that identifies the most influential business leaders in Wisconsin.

Chris Miskel joined Versiti as president and CEO in 2017, bringing with him more than two decades of health care leadership. Under his guidance, Versiti has expanded its lifesaving, patient-centered mission and operations to Ohio (increasing its footprint to five states), has grown into a workforce of approximately 2,700 employees, and reports annual revenues exceeding $475 million. His leadership has helped position Versiti as a national leader in blood health, diagnostic services, and biomedical research.

One significant milestone during Chris Miskel’s tenure came in 2024, when Versiti Blood Research Institute broke ground on a 79,000-square-foot, state-of-the-art expansion, which will nearly double VBRI’s research capacity and generate an estimated $19 million in additional tax revenue for Wisconsin over the next 30 years. This expansion underscores Versiti’s continued investment in scientific discovery and bringing cutting-edge research to the patient bedside.

Prior to joining Versiti, Miskel held leadership roles at Shire, Baxalta, Baxter International, and Eli Lilly and Co. He currently serves on Butler University’s board of trustees and the boards of Arthur J. Gallagher & Co. and the Medical College of Wisconsin, reflecting his ongoing commitment to education, health care, and community leadership.

Being named to the Wisconsin 275 is a well-deserved honor and under Chris Miskel’s leadership, Versiti continues to advance science, health care innovation, and lifesaving research.

Media Contact

Kristin Paltzer

kpaltzer@versiti.org

VBRI Researcher Dr. Francesca Ferraresso Named to Forbes 30 Under 30 for Healthcare

Francesca Ferraresso, PhD, a graduate student researcher in the Kastrup Laboratory at Versiti Blood Research Institute (VBRI), is CEO and co-founder of Syrina Therapeutics, a biotech startup developing next-generation RNA technology to treat rare and chronic diseases.